bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Epilepsy
 Resources from HONselect
Pot Compound Alters Levels of Seizure Drug in Epilepsy Patients
Experimental therapy shows interaction between cannabidiol and clobazam

By Robert Preidt

FRIDAY, Aug. 11, 2017 (HealthDay News) -- Scientists experimenting with the marijuana compound cannabidiol as an epilepsy treatment must evaluate any interactions with other anti-seizure drugs patients are taking, researchers report.

The new research from the University of Alabama at Birmingham suggests cannabidiol affects blood levels of several anti-seizure drugs, especially clobazam.

Cannabidiol (CBD) has shown promise as a potential anti-seizure compound in animal and human studies, the Alabama researchers said. They are testing it as a therapy for difficult-to-control epilepsy in 39 adults and 42 children.

Other drugs that the participants are taking include clobazam (Onfi), topiramate (Topamax), rufinamide (Banzel), zonisamide (Zonegran), valproate (Depakote) and eslicarbazepine.

Blood levels of some of the drugs changed significantly, but except for clobazam, they did not deviate from the normally accepted range when the patients took cannabidiol, the study found.

The researchers also found that adult patients taking clobazam reported feeling sedated more often.

The study was published Aug. 7 in the journal Epilepsia.

"A perception exists that since CBD is plant-based, that it is natural and safe; and while this may be mostly true, our study shows that CBD, just like other antiepileptic drugs, has interactions with other seizure drugs that patients and providers need to be aware of," study author Dr. Tyler Gaston said in a journal news release.

Another concern was noted with participants taking valproate and CBD. The study found they had higher liver function test results compared with participants not taking valproate.

Monitoring liver function would be important during treatment with CBD, the researchers said.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on epilepsy.

SOURCE: Epilepsia, news release, Aug. 7, 2017

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=725288

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Epilepsy
Seizures
Specialty Chemicals and Products
Cannabidiol
Research Personnel
Valproic Acid
Adult
Therapeutics
Blood
Liver
Liver Function Tests
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact